Literature DB >> 33379134

Cerebellar GABA Levels and Cognitive Interference in Parkinson's disease and Healthy Comparators.

Federica Piras1, Daniela Vecchio1, Francesca Assogna1, Clelia Pellicano1, Valentina Ciullo1, Nerisa Banaj1, Richard A E Edden2, Francesco E Pontieri3, Fabrizio Piras1, Gianfranco Spalletta1,4.   

Abstract

The neuroanatomical and molecular substrates for cognitive impairment in Parkinson Disease (PD) are far from clear. Evidence suggests a non-dopaminergic basis, and a crucial role for cerebellum in cognitive control in PD. We investigated whether a PD cognitive marker (response inhibition) was differently controlled by g-amino butyric acid (GABA) and/or by glutamate-glutamine (Glx) levels in the cerebellum of idiopathic PD patients, and healthy comparators (HC). Magnetic resonance spectroscopy of GABA/Glx (MEGA-PRESS acquisition sequence) was performed at 3 Tesla, and response inhibition assessed by the Stroop Word-Color Test (SWCT) and the Wisconsin Card Sorting Test (WCST). Linear correlations between cerebellar GABA/Glx levels, SWCT time/error interference effects and WCST perseverative errors were performed to test differences between correlation coefficients in PD and HC. Results showed that higher levels of mean cerebellar GABA were associated to SWCT increased time and error interference effects in PD, and the contrary in HC. Such effect dissociated by hemisphere, while correlation coefficients differences were significant in both right and left cerebellum. We conclude that MRS measured levels of cerebellar GABA are related in PD patients with decreased efficiency in filtering task-irrelevant information. This is crucial for developing pharmacological treatments for PD to potentially preserve cognitive functioning.

Entities:  

Keywords:  GABAergic signaling; MRS; Parkinson’s Disease; cerebellum; cognition; response inhibition

Year:  2020        PMID: 33379134      PMCID: PMC7823866          DOI: 10.3390/jpm11010016

Source DB:  PubMed          Journal:  J Pers Med        ISSN: 2075-4426


  46 in total

1.  The relative involvement of anterior cingulate and prefrontal cortex in attentional control depends on nature of conflict.

Authors:  M P Milham; M T Banich; A Webb; V Barad; N J Cohen; T Wszalek; A F Kramer
Journal:  Brain Res Cogn Brain Res       Date:  2001-12

2.  Neurotransmitter changes during interference task in anterior cingulate cortex: evidence from fMRI-guided functional MRS at 3 T.

Authors:  Simone Kühn; Florian Schubert; Ralf Mekle; Elisabeth Wenger; Bernd Ittermann; Ulman Lindenberger; Jürgen Gallinat
Journal:  Brain Struct Funct       Date:  2015-05-15       Impact factor: 3.270

3.  Mental disorders in Parkinson's disease after treatment with L-DOPA.

Authors:  P Rondot; J de Recondo; A Coignet; M Ziegler
Journal:  Adv Neurol       Date:  1984

4.  Decreased glutamic acid decarboxylase mRNA expression in prefrontal cortex in Parkinson's disease.

Authors:  Amélie C Lanoue; Alexandra Dumitriu; Richard H Myers; Jean-Jacques Soghomonian
Journal:  Exp Neurol       Date:  2010-09-09       Impact factor: 5.330

5.  The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery.

Authors:  G A Carlesimo; C Caltagirone; G Gainotti
Journal:  Eur Neurol       Date:  1996       Impact factor: 1.710

6.  Control of motor coordination by astrocytic tonic GABA release through modulation of excitation/inhibition balance in cerebellum.

Authors:  Junsung Woo; Joo Ok Min; Dae-Si Kang; Yoo Sung Kim; Guk Hwa Jung; Hyun Jung Park; Sunpil Kim; Heeyoung An; Jea Kwon; Jeongyeon Kim; Insop Shim; Hyung-Gun Kim; C Justin Lee; Bo-Eun Yoon
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-24       Impact factor: 11.205

7.  The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease.

Authors:  Gianfranco Spalletta; Robert G Robinson; Luca Cravello; Francesco E Pontieri; Mariangela Pierantozzi; Alessandro Stefani; Jeffrey D Long; Carlo Caltagirone; Francesca Assogna
Journal:  J Neurol       Date:  2014-04-03       Impact factor: 4.849

Review 8.  Response inhibition in Parkinson's disease: a meta-analysis of dopaminergic medication and disease duration effects.

Authors:  Peter Manza; Matthew Amandola; Vivekanand Tatineni; Chiang-Shan R Li; Hoi-Chung Leung
Journal:  NPJ Parkinsons Dis       Date:  2017-07-07

9.  Beyond Dopamine: GABA, Glutamate, and the Axial Symptoms of Parkinson Disease.

Authors:  Ruth L O'Gorman Tuura; Christian R Baumann; Heide Baumann-Vogel
Journal:  Front Neurol       Date:  2018-09-26       Impact factor: 4.003

10.  Comparing GABA-dependent physiological measures of inhibition with proton magnetic resonance spectroscopy measurement of GABA using ultra-high-field MRI.

Authors:  Katherine Dyke; Sophia E Pépés; Chen Chen; Soyoung Kim; Hilmar P Sigurdsson; Amelia Draper; Masud Husain; Parashkev Nachev; Penelope A Gowland; Peter G Morris; Stephen R Jackson
Journal:  Neuroimage       Date:  2017-03-09       Impact factor: 6.556

View more
  2 in total

1.  Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of α-synuclein and Parkin levels in rotenone-induced Parkinson's disease in rats.

Authors:  Sanaa Ahmed; Mahmoud M El-Sayed; Mohamed A Kandeil; Marwa M Khalaf
Journal:  Saudi Pharm J       Date:  2022-03-16       Impact factor: 4.562

2.  Reduced Hippocampal GABA+ Is Associated With Poorer Episodic Memory in Healthy Older Women: A Pilot Study.

Authors:  Joan Jiménez-Balado; Alexandra Ycaza Herrera; Kay Igwe; Lynda Klem; Korhan Buyukturkoglu; Andrei Irimia; Liu Chen; Jia Guo; Adam M Brickman; Teal S Eich
Journal:  Front Behav Neurosci       Date:  2021-08-26       Impact factor: 3.558

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.